# US 2003/0199430 A1 · Zinc formulations as a prophylactic treatment for the common cold

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0199430 A1
- Document ID: US20030199430A1
- Status: Published application
- Kind: A1
- Application number: 10/128,382
- Filed: 2002-04-23
- Published: 2003-10-23
- Earliest claimed: 2002-04-23
- Inventors: Richard A. Rosenbloom; Charles A. Phillips
- Web page: https://patentgrep.com/patent/US20030199430A1

## CPC

- A61K 31/315: Zinc compounds
- A61K 31/195: having an amino group
- A61K 31/555: containing heavy metals, e.g. hemin, hematin, melarsoprol
- A61K 33/30: Zinc; Compounds thereof
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Prophylactic treatment to reduce the incidence of common cold using formulations of zinc compounds with selected amino acids is described. The administration of such formulations to healthy individuals resulted in a statistically significant reduction in the incidence of common colds in healthy patients.

## Claims

### Claim 1

A method for the reduction of the incidence of a common cold in a human comprising the step of administering to a human an effective amount of a composition containing a zinc compound and an amino acid to reduce the incidence of a common cold in a human, said amino acid being capable of forming a complex with said zinc compound, and said amino acid being selected from the group consisting of glycine, L-alanine, D,L-alanine, L-2-aminobutyric acid, D,L-2-aminobutyric acid, L-valine, D,L-valine, L-isovaline, D,L-isovaline, L-leucine, D,L-leucine, D-isoleucine, D,L-isoleucine, L-lysine, and D,L-lysine; said composition containing from about 1 mg to about 5 mg of zinc for each gram of said composition, and the molar ratio of said amino acid to zinc being from about 2 to 20.

### Claim 2 (depends on 1)

The method of claim 1, wherein an effective amount of said composition provides from about 2 to about 200 mg of zinc per day to said human.

### Claim 3 (depends on 1)

The method of claim 1, wherein an effective amount of said composition provides from about 10 to about 150 mg of zinc per day to said human.

### Claim 4 (depends on 1)

The method of claim 1, wherein an effective amount of said composition provides from about 20 to about 100 mg of zinc per day to said human.

### Claim 5 (depends on 1)

The method of claim 1, wherein said amino acid is glycine.

### Claim 6 (depends on 1)

The method of claim 1, wherein said zinc compound is a zinc salt in the form of a sulfate, chloride, acetate, gluconate, ascorbate, citrate, aspartate, picolinate, orotate and transferrin salt.

### Claim 7 (depends on 1)

The method of claim 1, wherein said zinc compound is a complex of divalent zinc with said amino acid.

### Claim 8 (depends on 1)

The method of claim 1 wherein the zinc compound is zinc gluconate.

### Claim 9 (depends on 1)

The method of claim 1 wherein the zinc compound is zinc acetate.

### Claim 10 (depends on 1)

The method of claim 1 wherein the zinc compound is citrate.

### Claim 11 (depends on 4)

The method of claim 4, wherein said amino acid is glycine.

### Claim 12 (depends on 11)

The method of claim 11, wherein the zinc compound is zinc gluconate.